ANDA 200430, held by Nostrum Pharmaceuticals. Venlafaxine Hydrochloride.
As of Nov 19, 2026, ANDA 200430 (Venlafaxine Hydrochloride), held by Nostrum Pharmaceuticals, was first approved by FDA on Apr 4, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 4, 2023 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters